In most experimental settings, the HO-1 inhibitor Zinc Protoporphyrin IX (ZnPPIX) has been demonstrated to increase the susceptibility of cancer cells to apoptosis and enhance their sensitivity to cancer therapies. Here, HMOX1 is linked to cancer.